Anatara Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Brookes

Chief executive officer

AU$197.9k

Total compensation

CEO salary percentage	76.9%
CEO tenure	5.4yrs
CEO ownership	2.4%
Management average tenure	2.6yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Brookes's remuneration changed compared to Anatara Lifesciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$198k	AU$152k	-AU$2m
Mar 31 2023	n/a	n/a	-AU$2m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	-AU$2m
Jun 30 2022	AU$150k	AU$108k	-AU$3m
Mar 31 2022	n/a	n/a	-AU$2m
Dec 31 2021	n/a	n/a	-AU$2m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$84k	n/a	-AU$2m
Mar 31 2021	n/a	n/a	-AU$2m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$80k	n/a	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$35k	n/a	-AU$3m

Compensation vs Market: David's total compensation ($USD131.98K) is below average for companies of similar size in the Australian market ($USD298.21K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Brookes (64 yo)

5.4yrs

Tenure

AU$197,867

Compensation

Dr. David Lionel Brookes, MBBS, FACRRM, FAICD, serves as an Independent Non-Executive Director of Island Pharmaceuticals Limited since October 1, 2020. He serves as Managing Director of Anatara Lifescience...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Brookes	Executive Chairman & MD	no data	AU$197.87k	2.37% A$ 190.3k
John Michailidis	COO & Executive Director	2yrs	AU$118.79k	0.50% A$ 39.9k
Simon Erskine	Chief Development Officer	2.6yrs	AU$313.82k	no data
Jane Lowe	Managing Director of IR Department	no data	no data	no data
Stephen Denaro	Company Secretary	10.3yrs	no data	no data
Hayley van der Meer	Commercial Manager	no data	no data	no data

2.6yrs

Average Tenure

Experienced Management: ANR's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Brookes	Executive Chairman & MD	5.4yrs	AU$197.87k	2.37% A$ 190.3k
John Michailidis	COO & Executive Director	less than a year	AU$118.79k	0.50% A$ 39.9k
Peter Gibson	Chairman of Product Development Advisory Board	5.5yrs	no data	no data
Rebecca Burgell	Member of Product Development Advisory Board	5.5yrs	no data	no data
Jakob Begun	Member of Product Development Advisory Board	5.5yrs	no data	no data
Barry Campbell	Member of Product Development Advisory Board	5.5yrs	no data	no data
Simon Keely	Member of Product Development Advisory Board	5.5yrs	no data	no data
Nicholas Haslam	Non-Executive Director	1.5yrs	AU$37.74k	no data

5.5yrs

Average Tenure

Experienced Board: ANR's board of directors are considered experienced (5.5 years average tenure).

Anatara Lifesciences Management

Management criteria checks 3/4

Key information

Recent management updates

No independent directors

No independent directors

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Recent updates

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure